(RTTNews) – The drug brands Sanofi (SNYNF, SNY) and GlaxoSmithKline plc (GSK. L, GSK) announced on Monday that they were in complex discussions with the European Commission about the source of up to three hundred million doses of a COVID-19. Vaccine.
The candidate vaccine, developed through Sanofi in partnership with GSK, is in the generation of recombinant protein used through Sanofi to produce a flu vaccine and the established pandemic adjuvant generation of GSK.
The corporations said the doses for the EU would be manufactured in European countries, France, Belgium, Germany and Italy.
Sanofi, which leads the clinical progression and registration of the COVID-19 vaccine, expects Phase 1/2 to begin in September, followed by Phase 3 through the end of 2020.
GSK and Sanofi have already decided through Operation Warp Speed of the United States government to supply one hundred million doses of the COVID-19 recombinant protein vaccine.
They have also signed an agreement with the United States, where they have a long-standing partnership with the Advanced Biomedical Research and Development Authority.